600276 恒瑞医药
已收盘 05-27 15:00:00
资讯
新帖
简况
低位制药板块韧性凸显，华宝基金药ETF（562050）午后逆市拉升！权重股恒瑞医药冲高4%，中药龙头集体飘红
新浪基金 · 14:22
低位制药板块韧性凸显，华宝基金药ETF（562050）午后逆市拉升！权重股恒瑞医药冲高4%，中药龙头集体飘红
恒瑞医药(600276.SH)：HRS-1635片获得药物临床试验批准通知书
智通财经 · 05-26 16:49
恒瑞医药(600276.SH)：HRS-1635片获得药物临床试验批准通知书
恒瑞医药：公司2025年度利润分配方案经公司2025年年度股东会审议通过
证券日报 · 05-25 20:21
恒瑞医药：公司2025年度利润分配方案经公司2025年年度股东会审议通过
恒瑞医药：2025年公司创新药销售收入163.42亿元
证券日报 · 05-22
恒瑞医药：2025年公司创新药销售收入163.42亿元
恒瑞医药：每股派0.2元，股权登记日为5月26日
南方财经网 · 05-20
恒瑞医药：每股派0.2元，股权登记日为5月26日
深耕肠外营养领域，恒瑞医药新产品获批强化管线矩阵｜医药早参
每日经济新闻 · 05-20
深耕肠外营养领域，恒瑞医药新产品获批强化管线矩阵｜医药早参
恒瑞医药(01276)：ω-3 甘油三酯（2%）中/长链脂肪乳/氨基酸（16）/葡萄糖（30%）获得药品注册批准
智通财经 · 05-19
恒瑞医药(01276)：ω-3 甘油三酯（2%）中/长链脂肪乳/氨基酸（16）/葡萄糖（30%）获得药品注册批准
恒瑞医药子公司复方营养注射液获批上市 累计研发投入约8390万元
财中社 · 05-19
恒瑞医药子公司复方营养注射液获批上市 累计研发投入约8390万元
Schroders PLC增持恒瑞医药(01276)66.3万股 每股作价约68.7港元
智通财经 · 05-18
Schroders PLC增持恒瑞医药(01276)66.3万股 每股作价约68.7港元
恒瑞医药：公司已有瑞拉芙普α、瑞康曲妥珠单抗、阿得贝利单抗等多款生物制品类创新药获批上市
每日经济新闻 · 05-18
恒瑞医药：公司已有瑞拉芙普α、瑞康曲妥珠单抗、阿得贝利单抗等多款生物制品类创新药获批上市
恒瑞医药：RSS0393乳胶获临床试验批准
南方财经网 · 05-14
恒瑞医药：RSS0393乳胶获临床试验批准
恒瑞医药(600276.SH)子公司SHR-3079注射液获批开展临床试验
智通财经 · 05-14
恒瑞医药(600276.SH)子公司SHR-3079注射液获批开展临床试验
携手推进肿瘤学、血液学及免疫学创新疗法 恒瑞医药与百时美施贵宝达成战略合作协议
经济参考网 · 05-13
携手推进肿瘤学、血液学及免疫学创新疗法 恒瑞医药与百时美施贵宝达成战略合作协议
恒瑞医药子公司获三项临床批件
财中社 · 05-13
恒瑞医药子公司获三项临床批件
恒瑞医药：SHR-3821注射液获临床试验批准
南方财经网 · 05-13
恒瑞医药：SHR-3821注射液获临床试验批准
大摩：恒瑞医药(01276)与BMS缔152亿美元战略合作 加速全球化进程
智通财经 · 05-13
大摩：恒瑞医药(01276)与BMS缔152亿美元战略合作 加速全球化进程
恒瑞医药与BMS刷新合作纪录；默沙东与多家药企签署协议
21世纪经济报道 · 05-13
恒瑞医药与BMS刷新合作纪录；默沙东与多家药企签署协议
与跨国药企BMS双向授权，恒瑞医药拿下152亿美元BD大单，股价为何冲高回落？
时代财经 · 05-12
与跨国药企BMS双向授权，恒瑞医药拿下152亿美元BD大单，股价为何冲高回落？
跨国巨头再现百亿美元级“天价”收购
第一财经 · 05-12
跨国巨头再现百亿美元级“天价”收购
港股异动 | 恒瑞医药(01276)最高涨超16% 与百时美施贵宝达成战略合作协议 潜在总交易额达152亿美元
智通财经网 · 05-12
港股异动 | 恒瑞医药(01276)最高涨超16% 与百时美施贵宝达成战略合作协议 潜在总交易额达152亿美元
加载更多
公司概况
公司名称：
江苏恒瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。
发行价格：
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":50.37,"timestamp":1779865200000,"preClose":49,"halted":0,"volume":96115293,"delay":0,"changeRate":0.028,"floatShares":6379000000,"shares":6637000000,"eps":1.2233,"marketStatus":"已收盘","change":1.37,"latestTime":"05-27 15:00:00","open":48.88,"high":51.3,"low":48.45,"amount":4801000000,"amplitude":0.0582,"askPrice":50.37,"askSize":32,"bidPrice":50.36,"bidSize":119,"shortable":0,"etf":0,"ttmEps":1.2233,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779931800000},"marketStatusCode":5,"adr":0,"adjPreClose":49,"symbolType":"stock","openAndCloseTimeList":[[1779845400000,1779852600000],[1779858000000,1779865200000]],"highLimit":53.9,"lowLimit":44.1,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":5.25,"roa":"--","peRate":41.175509,"roe":"4.15%","epsLYR":1.19,"committee":-0.020852,"marketValue":334316000000,"turnoverRate":0.0151,"status":0,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":60.1,"timestamp":1779868254262,"preClose":59.65,"halted":0,"volume":5631238,"delay":0,"premium":"+3.31"},"floatMarketCap":321310000000},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2638957196","title":"低位制药板块韧性凸显，华宝基金药ETF（562050）午后逆市拉升！权重股恒瑞医药冲高4%，中药龙头集体飘红","url":"https://stock-news.laohu8.com/highlight/detail?id=2638957196","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638957196?lang=zh_cn&edition=full","pubTime":"2026-05-27 14:22","pubTimestamp":1779862920,"startTime":"0","endTime":"0","summary":"5月27日午后，A股突发跳水，沪指失守4100点。制药板块局部异动，权重龙头恒瑞医药快速拉升翻红，一度冲高超4%；中药股逆市表现，云南白药、以岭药业、东阿阿胶、片仔癀等集体飘红。 场内唯一表征制药板块整体行情的药ETF华宝午后自深水区直线拉升，截至发稿跌0.22%，沪指跌1.41%。 低位布局“创新药+中药”，认准场内唯一药ETF华宝及其场外联接基金，汇聚A股50大龙头药企，在重仓创新药的同时，有约25%的权重为中药。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-05-27/doc-inhzikrs0846612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2097828714.EUR","LU2488822045.USD","BK4588","LU1580142542.USD","LU2328871848.SGD","BK0188","BK1191","LU2289578879.USD","LU2097828631.EUR","600276","BK0060","LU2097828805.USD","LU1023057109.AUD","BK1574","LU1255011170.USD","LU1820825898.SGD","BK0183","LU1655091616.SGD","LU0405327494.USD","LU1969619763.USD","LU2580892789.USD","LU1781817850.SGD","LU0359202008.SGD","BK4550","BK0196","BK4585","LU1997244956.HKD","LU2097828474.EUR","BK0012","LU1146622755.USD","BK0239","BK0028","LU2543165471.USD","LU2097828557.USD","LU1064130708.USD","LU2148510915.USD","FDN","LU1997245094.SGD","562050","LU0359201612.USD","LU0405327148.USD","LU2495084118.USD","LU2580892862.HKD","01276","LU1328615791.USD","LU0359201885.HKD","LU1064131003.USD","01477","LU1997245177.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638592066","title":"恒瑞医药(600276.SH)：HRS-1635片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2638592066","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638592066?lang=zh_cn&edition=full","pubTime":"2026-05-26 16:49","pubTimestamp":1779785384,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司成都盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS-1635片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-1635片是公司自主研发的创新型抗肿瘤药物，拟用于治疗B细胞恶性肿瘤。经查询，目前国内外暂无同类药物获批上市。截至目前，HRS-1635片相关项目累计研发投入约2,360万元(未经审计)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445986.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","LU1146622755.USD","LU1580142542.USD","LU2495084118.USD","LU2097828631.EUR","BK1191","LU2580892862.HKD","BK0196","BK0060","LU1820825898.SGD","LU2097828557.USD","LU0405327148.USD","LU2148510915.USD","LU1064130708.USD","LU1655091616.SGD","LU1997245094.SGD","01276","LU1969619763.USD","BK0188","LU0405327494.USD","LU1023057109.AUD","LU2289578879.USD","LU1064131003.USD","BK0239","LU1997245177.USD","LU2097828714.EUR","LU2580892789.USD","BK0183","LU2097828474.EUR","LU2328871848.SGD","BK0028","LU1255011170.USD","LU0359201885.HKD","LU2543165471.USD","LU1328615791.USD","LU0359202008.SGD","LU2488822045.USD","LU2097828805.USD","600276","LU1997244956.HKD","LU1781817850.SGD","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638558983","title":"恒瑞医药：公司2025年度利润分配方案经公司2025年年度股东会审议通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2638558983","media":"证券日报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638558983?lang=zh_cn&edition=full","pubTime":"2026-05-25 20:21","pubTimestamp":1779711660,"startTime":"0","endTime":"0","summary":"证券日报网讯5月25日，恒瑞医药在互动平台回答投资者提问时表示，公司2025年度利润分配方案经公司2025年年度股东会审议通过，将按既定方案进行，具体详见公司在交易所网站发布的公告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605253748385364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1328615791.USD","LU1820825898.SGD","01276","LU0405327148.USD","LU2289578879.USD","LU2580892862.HKD","BK0028","LU1580142542.USD","BK1191","LU2097828805.USD","BK0060","LU2097828474.EUR","BK0012","LU2097828631.EUR","LU1969619763.USD","LU2097828557.USD","BK0183","LU1023057109.AUD","LU1655091616.SGD","LU0359201612.USD","LU2097828714.EUR","LU2580892789.USD","LU2488822045.USD","LU2148510915.USD","LU1146622755.USD","600276","LU1064130708.USD","LU1255011170.USD","LU1997245094.SGD","LU2495084118.USD","BK0188","LU0359201885.HKD","LU1997245177.USD","LU0359202008.SGD","LU2328871848.SGD","LU1781817850.SGD","LU1997244956.HKD","LU0405327494.USD","LU2543165471.USD","BK0239","BK0196","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637126963","title":"恒瑞医药：2025年公司创新药销售收入163.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2637126963","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637126963?lang=zh_cn&edition=full","pubTime":"2026-05-22 20:59","pubTimestamp":1779454740,"startTime":"0","endTime":"0","summary":"证券日报网讯5月22日，恒瑞医药在互动平台回答投资者提问时表示，公司坚持科技创新战略，已在中国获批上市24款1类创新药、5款2类新药，另有100多个自主创新产品正在临床开发，400余项临床试验在国内外开展。经营业绩方面，创新成果转化高效赋能，创新药销售引领业绩增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605223747010910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1328615791.USD","LU1820825898.SGD","01276","LU0405327148.USD","LU2289578879.USD","LU2580892862.HKD","BK0028","BK1574","LU1580142542.USD","BK1191","LU2097828805.USD","BK0060","LU2097828474.EUR","BK0012","LU2097828631.EUR","LU1969619763.USD","LU2097828557.USD","BK0183","BK1161","LU1023057109.AUD","LU1655091616.SGD","LU0359201612.USD","LU2097828714.EUR","LU2580892789.USD","LU2488822045.USD","LU2148510915.USD","LU1146622755.USD","600276","LU1064130708.USD","LU1255011170.USD","LU1997245094.SGD","LU2495084118.USD","BK0188","LU0359201885.HKD","LU1997245177.USD","LU0359202008.SGD","LU2328871848.SGD","LU1781817850.SGD","LU1997244956.HKD","LU0405327494.USD","159992","LU2543165471.USD","BK0239","BK0196","06978","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636845172","title":"恒瑞医药：每股派0.2元，股权登记日为5月26日","url":"https://stock-news.laohu8.com/highlight/detail?id=2636845172","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636845172?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:21","pubTimestamp":1779272460,"startTime":"0","endTime":"0","summary":"南财智讯5月20日电，恒瑞医药发布2025年年度权益分派实施公告，公司本次利润分配方案为每股派发现金红利0.2元（含税），共计派发现金红利12.74亿元。本次权益分派股权登记日为2026年5月26日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203743627742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2580892789.USD","LU1997244956.HKD","LU1997245094.SGD","BK0183","LU1023057109.AUD","LU2097828631.EUR","LU2495084118.USD","BK0188","LU1997245177.USD","BK0012","LU1820825898.SGD","LU2543165471.USD","LU0359201885.HKD","LU1580142542.USD","LU0405327494.USD","LU2097828714.EUR","BK0060","LU0359202008.SGD","LU1781817850.SGD","LU2328871848.SGD","LU2097828474.EUR","LU2289578879.USD","LU1064131003.USD","LU1146622755.USD","LU0405327148.USD","BK1191","LU2097828557.USD","LU2097828805.USD","LU1328615791.USD","BK0196","BK0028","LU1969619763.USD","LU2148510915.USD","LU1064130708.USD","BK0239","LU1255011170.USD","LU0359201612.USD","LU2488822045.USD","LU1655091616.SGD","LU2580892862.HKD","01276","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636896784","title":"深耕肠外营养领域，恒瑞医药新产品获批强化管线矩阵｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2636896784","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636896784?lang=zh_cn&edition=full","pubTime":"2026-05-20 09:22","pubTimestamp":1779240142,"startTime":"0","endTime":"0","summary":"截至5月19日收盘，市场探底回升，沪指、深成指先后翻红。医药ETF（512120）收平，港股通生物科技ETF（159102）上涨0.27%。相关个股中，恒瑞医药下跌1.6%、药明合联上涨3.28%、科伦博泰生物上涨1.27%、万泰生物下跌1.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605203742884813.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203742884813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1820825898.SGD","BK0060","09939","LU2097828805.USD","LU2097828714.EUR","01276","LU1997245177.USD","LU1023057109.AUD","LU1146622755.USD","BK0188","LU2097828631.EUR","LU2580892862.HKD","600276","LU2097828557.USD","LU2289578879.USD","LU2097828474.EUR","LU2488822045.USD","BK1191","LU0359201885.HKD","LU0405327148.USD","BK0012","BK0239","LU1255011170.USD","LU1969619763.USD","LU2148510915.USD","LU2543165471.USD","LU1997245094.SGD","LU1781817850.SGD","LU2328871848.SGD","LU1997244956.HKD","LU1580142542.USD","BK1161","BK0196","BK0028","BK1515","LU0359201612.USD","LU1064130708.USD","LU1064131003.USD","LU1655091616.SGD","LU1328615791.USD","159938","BK1574","LU2495084118.USD","LU2580892789.USD","BK0183","LU0359202008.SGD","LU0405327494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636837763","title":"恒瑞医药(01276)：ω-3 甘油三酯（2%）中/长链脂肪乳/氨基酸（16）/葡萄糖（30%）获得药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636837763","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636837763?lang=zh_cn&edition=full","pubTime":"2026-05-19 18:18","pubTimestamp":1779185930,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，江苏恒瑞医药股份有限公司子公司福建盛迪医药有限公司收到国家药品监督管理局的通知，批准公司 ω-3 甘油三酯(2%)中/长链脂肪乳/氨基酸/葡萄糖(30%)注射液上市。截至目前，ω-3 甘油三酯(2%)中/长链脂肪乳/氨基酸/葡萄糖(30%)注射液相关项目累计研发投入约 8,390 万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01276","BK1191","600276","BK0188","LU1023057109.AUD","LU2097828474.EUR","LU1146622755.USD","LU1255011170.USD","LU1064131003.USD","LU2097828805.USD","LU1969619763.USD","LU1997244956.HKD","LU0359201612.USD","LU1997245177.USD","BK0183","LU1781817850.SGD","LU2580892789.USD","LU1820825898.SGD","BK0028","BK0196","LU2289578879.USD","LU2328871848.SGD","LU2488822045.USD","LU1328615791.USD","LU1580142542.USD","LU1997245094.SGD","LU2097828714.EUR","LU2495084118.USD","LU0405327494.USD","BK0012","LU2097828631.EUR","LU0405327148.USD","LU1064130708.USD","LU0359201885.HKD","LU2097828557.USD","LU2543165471.USD","BK0060","LU2580892862.HKD","LU0359202008.SGD","LU1655091616.SGD","LU2148510915.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636563834","title":"恒瑞医药子公司复方营养注射液获批上市 累计研发投入约8390万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636563834","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636563834?lang=zh_cn&edition=full","pubTime":"2026-05-19 17:12","pubTimestamp":1779181920,"startTime":"0","endTime":"0","summary":"5月19日，恒瑞医药（600276/01276）发布公告，公司子公司福建盛迪医药有限公司收到国家药品监督管理局的通知，批准公司ω-3甘油三酯（2%）中/长链脂肪乳/氨基酸（16）/葡萄糖（30%）注射液上市。该药品为处方药，注册分类为化学药品3类，适用于当口服或肠内营养无法进行、不足或有禁忌的中重度分解代谢成人患者。截至目前，相关项目累计研发投入约为8390万元（未经审计）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605193742055768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","LU2543165471.USD","LU1997245177.USD","BK0012","LU1997244956.HKD","LU1023057109.AUD","01276","LU1781817850.SGD","LU1969619763.USD","LU2580892789.USD","LU1255011170.USD","BK0188","LU1655091616.SGD","BK0060","LU1064131003.USD","LU1580142542.USD","LU2097828714.EUR","LU2495084118.USD","IPOS","BK0183","LU1820825898.SGD","BK0196","LU2097828631.EUR","LU0359202008.SGD","LU1997245094.SGD","LU2097828474.EUR","LU1146622755.USD","LU2097828557.USD","LU0405327494.USD","LU0359201885.HKD","LU2097828805.USD","LU1064130708.USD","LU2328871848.SGD","600276","LU0405327148.USD","LU0359201612.USD","LU2488822045.USD","LU1328615791.USD","LU2580892862.HKD","LU2289578879.USD","LU2148510915.USD","BK0028","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636078106","title":"Schroders PLC增持恒瑞医药(01276)66.3万股 每股作价约68.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636078106","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636078106?lang=zh_cn&edition=full","pubTime":"2026-05-18 19:38","pubTimestamp":1779104328,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，5月12日，Schroders PLC增持恒瑞医药(01276)66.3万股，每股作价68.7041港元，总金额约为4555.08万港元。增持后最新持股数目为1317.12万股，持股比例为5.1%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0405327148.USD","LU1146622755.USD","LU1328615791.USD","LU2488822045.USD","LU1023057109.AUD","LU2097828631.EUR","LU2328871848.SGD","LU1820825898.SGD","LU0359202008.SGD","BK0183","LU1580142542.USD","LU2580892862.HKD","BK0012","BK0060","BK0188","BK0239","LU2097828557.USD","01276","LU2543165471.USD","LU1655091616.SGD","BK1191","LU0359201612.USD","LU1997244956.HKD","BK0196","BK0028","LU0405327494.USD","LU2289578879.USD","LU1064130708.USD","600276","LU1781817850.SGD","LU2148510915.USD","LU1255011170.USD","LU2097828474.EUR","LU2097828805.USD","LU1997245177.USD","EWH","LU0359201885.HKD","LU1997245094.SGD","LU1969619763.USD","LU2495084118.USD","LU2580892789.USD","LU1064131003.USD","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636026816","title":"恒瑞医药：公司已有瑞拉芙普α、瑞康曲妥珠单抗、阿得贝利单抗等多款生物制品类创新药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2636026816","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636026816?lang=zh_cn&edition=full","pubTime":"2026-05-18 16:48","pubTimestamp":1779094139,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：你好，贵司2025年新成立的生物制药事业部，请问在生物制药方面有什么新的进展？","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605183740505938.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605183740505938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2580892862.HKD","LU2097828805.USD","LU1328615791.USD","BK1191","LU1580142542.USD","LU1969619763.USD","LU2580892789.USD","LU1146622755.USD","LU2289578879.USD","IPOS","01276","LU2495084118.USD","LU1781817850.SGD","LU1997244956.HKD","BK0183","BK0196","LU0405327494.USD","LU1064131003.USD","06978","LU1997245177.USD","LU1997245094.SGD","LU0405327148.USD","LU2148510915.USD","BK0060","LU2097828631.EUR","LU0359201612.USD","159992","BK0028","LU2328871848.SGD","BK0239","LU1820825898.SGD","LU2097828714.EUR","LU1655091616.SGD","600276","BK1574","LU0359202008.SGD","BK1161","LU2543165471.USD","BK0188","BK0012","LU1255011170.USD","LU0359201885.HKD","LU2488822045.USD","LU1064130708.USD","LU2097828557.USD","LU1023057109.AUD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635792414","title":"恒瑞医药：RSS0393乳胶获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2635792414","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635792414?lang=zh_cn&edition=full","pubTime":"2026-05-14 16:37","pubTimestamp":1778747820,"startTime":"0","endTime":"0","summary":"南财智讯5月14日电，恒瑞医药公告，RSS0393乳胶收到国家药品监督管理局《药物临床试验批准通知书》，同意本品开展用于特应性皮炎治疗的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605143737468040.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0359201612.USD","LU2097828805.USD","BK0028","BK0239","LU0359202008.SGD","600276","LU2097828474.EUR","LU2328871848.SGD","LU1997244956.HKD","LU1969619763.USD","LU1997245094.SGD","LU2495084118.USD","LU2097828714.EUR","LU1064130708.USD","LU1781817850.SGD","LU2580892789.USD","LU1255011170.USD","LU1655091616.SGD","LU2097828557.USD","LU0359201885.HKD","LU2580892862.HKD","LU1820825898.SGD","BK0196","LU0405327148.USD","BK0183","LU0405327494.USD","BK0060","LU2289578879.USD","LU1146622755.USD","LU1328615791.USD","LU2543165471.USD","LU1997245177.USD","LU2097828631.EUR","BK0188","LU2148510915.USD","BK1191","LU2488822045.USD","LU1064131003.USD","BK0012","LU1580142542.USD","01276","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635792748","title":"恒瑞医药(600276.SH)子公司SHR-3079注射液获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2635792748","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635792748?lang=zh_cn&edition=full","pubTime":"2026-05-14 16:36","pubTimestamp":1778747819,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理局核准签发关于SHR-3079注射液《药物临床试验批准通知书》，将于近期开展临床试验。据悉，SHR-3079注射液是公司自主研发的创新型抗肿瘤药物，拟用于治疗B细胞非霍奇金淋巴瘤。经查询，目前国内外尚无同类药物获批上市。截至目前，SHR-3079注射液相关项目累计研发投入约为2340万元(未经审计)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01276","LU1997245094.SGD","BK0012","LU2097828557.USD","LU0405327148.USD","BK0239","LU2543165471.USD","LU1255011170.USD","LU1023057109.AUD","BK0183","LU1328615791.USD","LU1655091616.SGD","LU0359201885.HKD","LU0359201612.USD","LU1997244956.HKD","BK0060","LU2289578879.USD","LU0359202008.SGD","BK0196","BK1191","BK0188","BK0028","LU1146622755.USD","LU2097828474.EUR","LU2580892862.HKD","LU2097828714.EUR","LU1969619763.USD","LU2580892789.USD","LU2097828631.EUR","LU2328871848.SGD","LU2488822045.USD","LU1064131003.USD","LU1820825898.SGD","LU1064130708.USD","LU0405327494.USD","LU2495084118.USD","LU1781817850.SGD","LU2097828805.USD","600276","LU1997245177.USD","LU2148510915.USD","LU1580142542.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635320782","title":"携手推进肿瘤学、血液学及免疫学创新疗法 恒瑞医药与百时美施贵宝达成战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2635320782","media":"经济参考网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635320782?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:20","pubTimestamp":1778664054,"startTime":"0","endTime":"0","summary":"5月12日，江苏恒瑞医药股份有限公司(简称“恒瑞医药”，600276.SH;01276.HK)与百时美施贵宝公司(简称“BMS”，NYSE：BMY)宣布达成全球战略合作及许可协议，共同推进13款涵盖肿瘤学、血液学及免疫学领域的早期创新项目。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133735980065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1023057109.AUD","BMY","LU2125154778.USD","LU0405327494.USD","01276","IE0009355771.USD","600276","BK0012","LU0225284248.USD","LU0306807586.USD","LU2495084118.USD","LU2242652126.USD","IE00BFXG1179.USD","LU1585245621.USD","LU0359201612.USD","LU0985481810.HKD","BK4007","LU0237698245.USD","LU1261432733.SGD","LU1868836591.USD","LU1868836757.USD","LU1146622755.USD","BK0183","LU1670710661.SGD","LU2580892862.HKD","LU1670711040.USD","LU1820825898.SGD","LU2328871848.SGD","LU1868837300.USD","LU1997245177.USD","BK0060","LU1064131003.USD","LU1093756168.USD","LU2242646821.SGD","LU0432979614.USD","LU0321505439.SGD","LU1571399168.USD","LU2097828474.EUR","LU2097828714.EUR","LU0225771236.USD","BK4532","LU0405327148.USD","LU2097828805.USD","LU2097828557.USD","LU1655091616.SGD","LU1670710588.SGD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU2543165471.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635040892","title":"恒瑞医药子公司获三项临床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2635040892","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635040892?lang=zh_cn&edition=full","pubTime":"2026-05-13 16:52","pubTimestamp":1778662320,"startTime":"0","endTime":"0","summary":"5月13日，恒瑞医药（600276/01276）发布公告，公司子公司苏州盛迪亚生物医药有限公司、上海盛迪医药有限公司近日收到国家药品监督管理局核准签发的关于SHR-3821注射液、阿得贝利单抗注射液、瑞拉芙普α注射液的《药物临床试验批准通知书》，将于近期开展临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133735945731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1328615791.USD","LU1820825898.SGD","01276","LU0405327148.USD","LU2289578879.USD","LU2580892862.HKD","BK0028","LU1580142542.USD","BK1191","LU2097828805.USD","BK0060","LU2097828474.EUR","BK0012","LU2097828631.EUR","LU1969619763.USD","LU2097828557.USD","BK0183","LU1023057109.AUD","LU1655091616.SGD","LU0359201612.USD","LU2097828714.EUR","LU2580892789.USD","LU2488822045.USD","LU2148510915.USD","LU1146622755.USD","600276","LU1064130708.USD","LU1255011170.USD","LU1997245094.SGD","LU2495084118.USD","BK0188","LU0359201885.HKD","LU1997245177.USD","LU0359202008.SGD","LU2328871848.SGD","LU1781817850.SGD","LU1997244956.HKD","LU0405327494.USD","LU2543165471.USD","BK0239","BK0196","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635920479","title":"恒瑞医药：SHR-3821注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2635920479","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635920479?lang=zh_cn&edition=full","pubTime":"2026-05-13 16:47","pubTimestamp":1778662020,"startTime":"0","endTime":"0","summary":"南财智讯5月13日电，恒瑞医药公告，SHR-3821注射液收到国家药品监督管理局《药物临床试验批准通知书》，同意开展SHR-3821注射液联合其他抗肿瘤治疗在实体瘤患者中的安全性、耐受性和有效性的多中心、开放的Ib/II期临床研究。该药为公司自主研发的人源化抗体药物，拟用于治疗晚期实体瘤，可通过在肿瘤组织中特异性激活免疫细胞发挥抗肿瘤作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133735943423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1328615791.USD","LU1820825898.SGD","01276","LU0405327148.USD","LU2289578879.USD","LU2580892862.HKD","BK0028","LU1580142542.USD","BK1191","LU2097828805.USD","BK0060","LU2097828474.EUR","BK0012","LU2097828631.EUR","LU1969619763.USD","LU2097828557.USD","BK0183","LU1023057109.AUD","LU1655091616.SGD","LU0359201612.USD","LU2097828714.EUR","LU2580892789.USD","LU2488822045.USD","LU2148510915.USD","LU1146622755.USD","600276","LU1064130708.USD","LU1255011170.USD","LU1997245094.SGD","LU2495084118.USD","BK0188","LU0359201885.HKD","LU1997245177.USD","LU0359202008.SGD","LU2328871848.SGD","LU1781817850.SGD","LU1997244956.HKD","LU0405327494.USD","LU2543165471.USD","BK0239","BK0196","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635027823","title":"大摩：恒瑞医药(01276)与BMS缔152亿美元战略合作 加速全球化进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2635027823","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635027823?lang=zh_cn&edition=full","pubTime":"2026-05-13 10:43","pubTimestamp":1778640196,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹利发布研报称，恒瑞医药(01276)与百时美施贵宝宣布一项涵盖13个临床前资产的全球战略合作，总交易价值达152亿美元(下同)。当中包括6亿美元预付款、2027至2028年合共3.5亿美元周年付款、最高143亿美元里程碑付款，以及分级销售里程权利金。该行维持恒瑞为中国医疗保健行业首选股，予“增持”评级，H股目标价92港元。该行认为，这项涵盖多种形式及资产模态的战略合作，进一步验证恒瑞医药的早期研发平台及提升的全球化能力。除了短期现金收益外，双向合作结构及共同开发与商业化选项，亦有望加快恒瑞的全球化步伐，并为其在中国市场不断扩展的免疫学产品组合带来商业协同效应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d8fdac8d3d9097cb034fb43ab6bd5883","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441038.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359201612.USD","LU2097828805.USD","BK0028","BK0239","LU0359202008.SGD","600276","LU2097828474.EUR","LU2328871848.SGD","LU1997244956.HKD","LU1969619763.USD","LU1997245094.SGD","LU2495084118.USD","LU2097828714.EUR","LU1064130708.USD","LU1781817850.SGD","LU2580892789.USD","LU1255011170.USD","LU1655091616.SGD","LU2097828557.USD","LU0359201885.HKD","LU2580892862.HKD","LU1820825898.SGD","BK0196","LU0405327148.USD","BK0183","LU0405327494.USD","BK0060","LU2289578879.USD","LU1146622755.USD","LU1328615791.USD","LU2543165471.USD","LU1997245177.USD","LU2097828631.EUR","BK0188","LU2148510915.USD","BK1191","LU2488822045.USD","LU1064131003.USD","BK0012","BMS","LU1580142542.USD","01276","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635221419","title":"恒瑞医药与BMS刷新合作纪录；默沙东与多家药企签署协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2635221419","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635221419?lang=zh_cn&edition=full","pubTime":"2026-05-13 08:02","pubTimestamp":1778630577,"startTime":"0","endTime":"0","summary":"政策动向国家药监局局长黄果会见新加坡卫生科学局局长蔡瑞文双方就创新医疗器械等议题深入交换意见国家药监局局长黄果5月11日在京会见了来访的新加坡卫生科学局局长蔡瑞文一行，并签署《中华人民共和国国家药品监督管理局与新加坡共和国卫生科学局监管合作谅解备忘录》。双方就细胞和基因治疗、创新医疗器械及人工智能产品监管等议题深入交换意见。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605133735150673.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"d8fdac8d3d9097cb034fb43ab6bd5883","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133735150673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1430594728.SGD","LU0965508806.USD","LU1997245094.SGD","IE00B1BXHZ80.USD","LU1116320737.USD","LU2491050071.SGD","SG9999001176.SGD","BK0239","LU2543165471.USD","LU1061106388.HKD","LU1941712348.USD","BK0183","IE00BFTCPJ56.SGD","LU0985320562.USD","LU0320765646.SGD","BK0188","LU1146622755.USD","LU1037948897.HKD","LU2023250843.SGD","LU1989772923.USD","LU1037948541.HKD","002022","LU0265550359.USD","LU0266013472.USD","LU0965509283.SGD","LU0208291251.USD","LU2106854487.HKD","IE00BLSP4452.SGD","LU1934455863.HKD","LU0405327494.USD","IE00BSNM7G36.USD","LU1781817850.SGD","IE000M9KFDE8.USD","SG9999014559.SGD","LU0130517989.USD","BK4516","SG9999014542.SGD","LU1917777945.USD","LU1580142542.USD","01276","BK0012","LU1585245621.USD","LU1291159041.SGD","LU0965509101.SGD","LU1069347547.HKD","LU2112291526.USD","LU1255011170.USD","BK4550","LU1023057109.AUD","SG9999014567.USD","LU2468319806.SGD","LU1997244956.HKD","BK4585","LU0106261372.USD","IE00BLSP4239.USD","BK4534","SG9999001176.USD","BK0028","IE0002141913.USD","LU2324357040.USD","BK4588","SG9999015358.SGD","IE00BJJMRZ35.SGD","LU1929549753.HKD","LU1162221912.USD","LU2097828714.EUR","LU2491050154.USD","LU2580892789.USD","LU2097828631.EUR","IE00B2B36J28.USD","LU1201861249.SGD","MRK","LU2328871848.SGD","LU2361045086.USD","LU1116320901.HKD","LU0477156953.USD","LU1064131003.USD","LU1064130708.USD","LU2495084118.USD","301206","LU0006306889.USD","LU1974910355.USD","LU1023059063.AUD","LU0868494708.USD","IE00B4R5TH58.HKD","LU2357627491.SGD","LU2097828557.USD","LU0405327148.USD","LU2360032135.SGD","SG9999015341.SGD","LU0122379950.USD","LU0211331839.USD","LU0859254822.USD","LU0648001328.SGD","LU0289739699.SGD","LU0359201612.USD","LU1093756325.SGD","LU2289578879.USD","LU0359202008.SGD","BK0196","BK1191","LU2125154778.USD","BK4007","LU2097828474.EUR","BK4559","LU0238689110.USD","LU1969619763.USD","LU1989771016.USD","LU2361044865.SGD","LU0098860793.USD","LU2089984988.USD","LU1699723380.USD","LU1066051225.USD","LU1093756168.USD","LU1934455194.USD","LU0965509010.AUD","LU1934455277.USD","IE00BJT1NW94.SGD","LU2148510915.USD","LU1066053197.SGD","IE00BN8TJ469.HKD","LU2491049909.HKD","LU1066051498.USD","LU1057294990.SGD","IE0009355771.USD","LU1066051811.HKD","SGXZ57979304.SGD","LU0130102774.USD","LU0058720904.USD","SG9999002224.SGD","LU0265550946.USD","LU0861579265.USD","LU1941712264.USD","LU2125154935.USD","LU1328615791.USD","LU1655091616.SGD","LU0359201885.HKD","BK0060","LU2461242641.AUD","LU2023250504.SGD","LU0203345920.USD","LU0203347892.USD","IE00BBT3K403.USD","LU0432979614.USD","LU0070302665.USD","688506","LU0942090050.USD","LU1035773651.USD","LU2580892862.HKD","SG9999002232.USD","SG9999014575.USD","LU2488822045.USD","LU1820825898.SGD","SG9999013999.USD","LU0980610538.SGD","LU1571399168.USD","LU2361044949.HKD","LU0320765489.SGD","LU0868494617.USD","SG9999001440.SGD","LU1983299246.USD","LU2097828805.USD","600276","BK4533","LU1997245177.USD","LU0234572021.USD","LU1989772840.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634248737","title":"与跨国药企BMS双向授权，恒瑞医药拿下152亿美元BD大单，股价为何冲高回落？","url":"https://stock-news.laohu8.com/highlight/detail?id=2634248737","media":"时代财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634248737?lang=zh_cn&edition=full","pubTime":"2026-05-12 22:26","pubTimestamp":1778595960,"startTime":"0","endTime":"0","summary":"5月12日，A股医药板块迎来重磅消息。医药“老大哥”恒瑞医药（600276.SH；01276.HK）午后股价直线拉升，A股盘中一度触及涨停，港股一度涨超16%。不过，市场的亢奋情绪并未持续至收盘。随后股价震荡回落，截至收盘，恒瑞医药A股、港股涨幅均收窄至4.84%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734861793.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0359201612.USD","LU2097828805.USD","BK0028","BK0239","LU0359202008.SGD","600276","LU2097828474.EUR","LU2328871848.SGD","LU1997244956.HKD","LU1969619763.USD","LU1997245094.SGD","LU2495084118.USD","LU2097828714.EUR","LU1064130708.USD","LU1781817850.SGD","LU2580892789.USD","LU1255011170.USD","LU1655091616.SGD","LU2097828557.USD","LU0359201885.HKD","LU2580892862.HKD","LU1820825898.SGD","BK0196","LU0405327148.USD","BK0183","LU0405327494.USD","BK0060","LU2289578879.USD","LU1146622755.USD","LU1328615791.USD","LU2543165471.USD","LU1997245177.USD","LU2097828631.EUR","BK0188","LU2148510915.USD","BK1191","LU2488822045.USD","LU1064131003.USD","BK0012","BMS","LU1580142542.USD","01276","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634291117","title":"跨国巨头再现百亿美元级“天价”收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2634291117","media":"第一财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634291117?lang=zh_cn&edition=full","pubTime":"2026-05-12 16:59","pubTimestamp":1778576361,"startTime":"0","endTime":"0","summary":"5月12日，恒瑞医药宣布，百时美施贵宝（BMS）与恒瑞医药达成授权协议，BMS将向恒瑞医药支付最高达9.5亿美元的相关付款，该协议的潜在总交易额可达约152亿美元。受该消息提振，恒瑞医药港股（1276.HK）股价一度上涨约15%。这项协议涵盖了恒瑞医药的13项创新项目，包括肿瘤学、血液学及免疫学。不过声明称，这些项目仍然处于早期研发阶段，尚未进入临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605123734535143.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734535143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01276","BK1191","600276","BK0188","LU1023057109.AUD","LU2097828474.EUR","LU1146622755.USD","LU1255011170.USD","LU1064131003.USD","LU2097828805.USD","LU1969619763.USD","LU1997244956.HKD","LU0359201612.USD","LU1997245177.USD","BK0183","LU1781817850.SGD","LU2580892789.USD","LU1820825898.SGD","BK0028","BK0196","LU2289578879.USD","LU2328871848.SGD","LU2488822045.USD","LU1328615791.USD","LU1580142542.USD","LU1997245094.SGD","LU2097828714.EUR","LU2495084118.USD","LU0405327494.USD","BK0012","BMS","LU2097828631.EUR","LU0405327148.USD","LU1064130708.USD","LU0359201885.HKD","LU2097828557.USD","LU2543165471.USD","BK0060","LU2580892862.HKD","LU0359202008.SGD","LU1655091616.SGD","LU2148510915.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634126909","title":"港股异动 | 恒瑞医药(01276)最高涨超16% 与百时美施贵宝达成战略合作协议 潜在总交易额达152亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634126909","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634126909?lang=zh_cn&edition=full","pubTime":"2026-05-12 13:35","pubTimestamp":1778564111,"startTime":"0","endTime":"0","summary":"恒瑞医药(01276)午后急升，最高涨超16%，截至发稿，涨6.21%，报70.15港元，成交额10.14亿港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260512/20260512133545_76516.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260512/20260512133545_76516.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d8fdac8d3d9097cb034fb43ab6bd5883","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1580142542.USD","LU0267386448.USD","IE00B2B36J28.USD","LU1074936037.SGD","LU1430594728.SGD","LU1820825898.SGD","LU1868836591.USD","LU1983299246.USD","LU1989771016.USD","LU2148510915.USD","LU1670711040.USD","LU2097828631.EUR","01276","LU0405327148.USD","LU2125154935.USD","BK0183","LU1093756325.SGD","LU1670710588.SGD","BK0012","BMY","LU1868836757.USD","LU1997245094.SGD","LU2242652126.USD","LU2097828714.EUR","LU1655091616.SGD","LU0306807586.USD","LU1064131003.USD","LU0456855351.SGD","BK0060","BK4581","LU1571399168.USD","600276","LU1585245621.USD","LU1969619763.USD","LU2488822045.USD","VXUS","LU2328871848.SGD","LU0868494617.USD","BK0028","LU2242646821.SGD","LU1093756168.USD","BK4585","LU1146622755.USD","LU0405327494.USD","LU0432979614.USD","LU1032466523.USD","BK0188","LU1997245177.USD","IE0002141913.USD","LU1323610961.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779868258646,"stockEarnings":[{"period":"1week","weight":-0.0463},{"period":"1month","weight":-0.1222},{"period":"3month","weight":-0.1497},{"period":"6month","weight":-0.2076},{"period":"1year","weight":-0.0778},{"period":"ytd","weight":-0.1741}],"compareEarnings":[{"period":"1week","weight":-0.0058},{"period":"1month","weight":0.016},{"period":"3month","weight":-0.0004},{"period":"6month","weight":0.0697},{"period":"1year","weight":0.2386},{"period":"ytd","weight":0.0445}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"458309人(较上一季度增加1.93%)","perCapita":"13918股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":" 江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}